We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+7.28%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$781M
AUM Growth
+$281M
Cap. Flow
+$296M
Cap. Flow %
37.86%
Top 10 Hldgs %
66.38%
Holding
71
New
25
Increased
8
Reduced
8
Closed
25

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$123M
2
NKTX icon
Nkarta
NKTX
+$60.3M
3
KROS icon
Keros Therapeutics
KROS
+$47.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$45.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$41.8M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$31.2M
2
BNTX icon
BioNTech
BNTX
+$19.7M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.9M
4
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$16.7M
5
AKBA icon
Akebia Therapeutics
AKBA
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$280M
$118M 15.15%
+3,136,981
New +$123M
KROS icon
2
Keros Therapeutics
KROS
$207M
$61.7M 7.9%
1,600,000
+1,200,000
+300% +$47.6M
NKTX icon
3
Nkarta
NKTX
$168M
$61.5M 7.88%
+2,047,178
New +$60.3M
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$58.5M 7.48%
1,173,188
-106,812
-8% -$4.32M
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
$46.9M 6%
850,000
+715,000
+530% +$45.4M
TGTX icon
6
TG Therapeutics
TGTX
$8.65B
$46.8M 5.99%
1,750,000
+900,000
+106% +$20.7M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.7B
$38.6M 4.94%
+275,000
New +$41.8M
DYN icon
8
Dyne Therapeutics
DYN
$4.19B
$32.4M 4.15%
+1,604,392
New +$35.2M
RPTX
9
DELISTED
Repare Therapeutics
RPTX
$30.1M 3.85%
976,894
+310,000
+46% +$8.21M
BTAI icon
10
BioXcel Therapeutics
BTAI
$26.4M
$23.8M 3.05%
34,375
+15,625
+83% +$11.7M
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$20.3M 2.6%
721,454
-205,000
-22% -$5.92M
LONA
12
LeonaBio Inc
LONA
$69.6M
$18.8M 2.41%
+102,081
New +$17.1M
CLDX icon
13
Celldex Therapeutics
CLDX
$2.83B
$17.8M 2.28%
1,200,000
-800,000
-40% -$9.37M
CMPS
14
Compass Pathways
CMPS
$1.54B
$17.4M 2.23%
+500,000
New +$18M
CYTK icon
15
Cytokinetics
CYTK
$10.9B
$16.2M 2.08%
750,000
-50,000
-6% -$1.17M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$15.3M 1.96%
+250,000
New +$12.7M
CALT
17
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$13.2M 1.69%
550,000
+250,000
+83% +$5.82M
BMY.RT
18
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$12.4M 1.58%
5,500,000
+1,500,000
+38% +$4.28M
KYMR icon
19
Kymera Therapeutics
KYMR
$9.19B
$9.72M 1.24%
+300,920
New +$9.19M
NRIX icon
20
Nurix Therapeutics
NRIX
$2.47B
$9.6M 1.23%
+275,000
New +$6.93M
HRMY icon
21
Harmony Biosciences
HRMY
$2.1B
$9.32M 1.19%
+275,000
New +$10M
ITOS
22
DELISTED
iTeos Therapeutics
ITOS
$7.4M 0.95%
+300,000
New +$8.07M
PNT
23
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.19M 0.92%
+500,000
New +$6.82M
AKUS
24
DELISTED
Akouos Inc
AKUS
$7.09M 0.91%
310,000
-140,000
-31% -$3.11M
COGT icon
25
Cogent Biosciences
COGT
$6.96B
$6.32M 0.81%
+675,000
New +$7.04M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2020 Portfolio in Review

As of Q3 2020, Logos Global Management held 71 positions worth $781M, up 56% from $500M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Logos Global Management deployed $296M of net new capital in Q3 2020, opening 25 new positions and adding to 8 existing holdings. Its largest new stake was ALX Oncology: 3,136,981 shares worth $118M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Celldex Therapeutics, an estimated $9.37M trimmed.

  • Logos Global Management's largest Q3 2020 buy was ALX Oncology: 3,136,981 shares worth $118M.
  • Logos Global Management added most to Keros Therapeutics in Q3 2020, an estimated $47.6M increase.
  • Logos Global Management's biggest Q3 2020 reduction was Celldex Therapeutics, cutting an estimated $9.37M.
  • Logos Global Management fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020, selling an estimated $31.2M.
  • Logos Global Management's ten largest holdings make up 66% of its $781M portfolio in Q3 2020.
  • Logos Global Management opened 25 new positions and closed 25 in Q3 2020.
  • Logos Global Management's portfolio value rose 56% quarter-over-quarter to $781M.

Based on Logos Global Management's 13F filing for Q3 2020, filed 16 Nov 2020.